India, May 4 -- Lunai Bioworks Inc. (LNAI), an AI-driven life sciences company, on Monday announced a $20 million preferred equity issuance to acquire intellectual property to strengthen its platform for developing drug delivery to the central nervous system.
The intellectual property (IP), acquired from to counterparties, will allow for the expansion of the company's central nervous system (CNS) platform, addressing a limitation in drug delivery that crosses the blood-brain-barrier (BBB) for effective treatment of neurological indications like Alzheimer's disease.
The acquired assets will be merged into the company's subsidiary, Lunai Bioworks IP Inc. On May 1, 2026, Lunai issued Series B Preferred Stock worth an aggregate value of $20 m...